Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Sponsor: Washington University School of Medicine
Summary
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2023-07-01
Completion Date
2026-08-01
Last Updated
2026-03-10
Healthy Volunteers
No
Interventions
Dasatinib
dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
quercetin
The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
Locations (1)
Washington University School of Medicine
St Louis, Missouri, United States